Amitriptyline and Paroxetine Treatment of Major Depression

• Status: Completed
• Trial end date: 2000-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Activation of the hypothalamus-pituitary-adrenal system is monitored using saliva cortisol sampling during the antidepressant treatment with amitriptyline and paroxetine in moderately to severely depressed patients. Additionally, serum and plasma are sampled during the 5-week study period in order to study endocrine and metabolic parameters.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Central Institute of Mental Health, Mannheim
• Treatments: Amitriptyline; Amitriptyline, perphenazine drug combination; Paroxetine

Criteria

Inclusion Criteria:

• age: above 18

• depression according DSM-IV

Exclusion Criteria:

• bipolar disorder

• substance dependency